Medication info
Rinategen Duo Tablet 2.5/850 mg

Rinategen Duo Tablet 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Albogen Korea Co., Ltd.
Appearance
Bright orange, bilaterally convex, oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201902608 · Approved 2019.04.25 · Insurance code 652607280

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medication should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's previous metformin dose. When this medication is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's previous metformin dose. When this medication is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may result in a change in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Medication).

Ingredients

Manufacturer
Albogen Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with dietary management and exercise to help patients with type 2 diabetes control their blood sugar levels. Particularly, the combination of linagliptin and metformin effectively manages blood sugar levels. This results in improved blood sugar control, aiding in diabetes management.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medication should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's previous metformin dose. When this medication is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's previous metformin dose. When this medication is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may result in a change in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Medication).

Precautions

This medication can cause a rare but very serious side effect called lactic acidosis; therefore, it should not be used in patients with impaired kidney function or those with severe infections, dehydration, or heart or liver diseases. Patients with allergies to any of the ingredients in this medication, those with type 1 diabetes, those with diabetic ketoacidosis, and women who are pregnant or breastfeeding should not take this medication. Caution is advised when using this medication in conjunction with other blood sugar-lowering drugs or insulin due to the risk of hypoglycemia, and dosages of other medications may need to be adjusted accordingly. Elderly patients with deteriorating kidney function or those taking medications that may affect kidney function should have regular kidney function tests, and this medication should be discontinued if kidney function worsens. Acute pancreatitis or skin blistering disorders may occur, so if abdominal pain or skin abnormalities occur during treatment, it is important to inform medical staff immediately. The metformin component may lower vitamin B12 levels, so regular monitoring of vitamin B12 levels is recommended for long-term use. This medication is not recommended during pregnancy, and women planning to become pregnant or currently pregnant must consult a doctor. In situations where kidney function may temporarily worsen due to surgery, radiation tests, etc., use of this medication should be temporarily discontinued, and resumed once kidney function recovers. The safety and efficacy in children and patients under 10 years of age have not been established, and it is advisable not to use it in these populations. The effects on driving or operating machinery are not clear, but caution is advised due to the risk of hypoglycemia. In case of overdose, severe side effects such as lactic acidosis may occur; therefore, it is essential to adhere to the prescribed dosage and visit a medical institution immediately if any abnormal symptoms arise. Store this medication away from moisture and direct sunlight, and keep it out of reach of children; avoid transferring it to other containers.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 128 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid-like lesions
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • viral upper respiratory infection
  • upper respiratory infection
  • gastroenteritis
  • hypercholesterolemia
  • insufficient control of diabetes
  • malnutrition
  • hyponatremia
  • dehydration
  • headache
  • sensory abnormalities
  • postherpetic neuralgia
  • hemiplegia
  • syncope
  • drowsiness
  • chest discomfort
  • asthenia
  • nosebleed
  • oropharyngeal pain
  • vocal disorder
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • periodontitis
  • folliculitis
  • influenza
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dyspepsia
  • stomatitis
  • increased serum creatinine
  • facial edema
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • dizziness
  • diabetic neuropathy
  • subdural effusion
  • palpitations
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature to preserve the effectiveness of the medication.

Appearance and packaging

Appearance

Bright orange, bilaterally convex, oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.